Previous 10 | Next 10 |
- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - EOS-984, a first-in-class program targeting a new mechanism of action in the a...
Summary iTeos Therapeutics, Inc. has a major deal with GSK, but a rival drug failed, bringing iTeos Therapeutics down. This happened once before with another program. iTeos Therapeutics has a lot of cash. iTeos Therapeutics, Inc. ( ITOS ) is a developer of immunotherap...
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Det...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developme...
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Det...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips You don’t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical scien...
iTeos Therapeutics ( NASDAQ: ITOS ) and Arcus Biosciences ( NYSE: RCUS ) were among notable decliners in pre-market trading Thursday after Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) CEO commented on its SKYSCRAPER-01 trial, which evaluated its anti-TIGIT immunotherapy tiragolum...
- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - Eleven clinical trials planned or ongoing against multiple tumor types, across three pipeline programs - EOS-984, a first-in-c...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Det...
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Mich...
News, Short Squeeze, Breakout and More Instantly...
iTeos Therapeutics Inc. Company Name:
ITOS Stock Symbol:
NASDAQ Market:
iTeos Therapeutics Inc. Website:
2024-05-22 01:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 07:00:04 ET Swayampakula Ramakanth from H.C. Wainwright issued a price target of $46.00 for ITOS on 2024-05-13 06:11:00. The adjusted price target was set to $46.00. At the time of the announcement, ITOS was trading at $17.44. ITOS currently trades -32.51% ver...
A look at the top 10 most actives in the United States Novavax Inc. (NVAX) rose 98.7% to $8.88 on volume of 168,692,127 shares AEye Inc. (LIDR) rose 115.0% to $2.58 on volume of 156,236,079 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 17.3% to $0.7609 on volume of 123,678,040 s...